Related Experiment Video
Updated: Jan 2, 2026
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)
12:24
Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test
Published on: March 23, 2013
14.1K
Diabetic Gastroparesis and Glycaemic Control
Ryan Jalleh1, Chinmay S Marathe2,3, Christopher K Rayner3,4
1Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Ryan.jalleh@sa.gov.au.
Current Diabetes Reports
|December 4, 2019
Summary
Diabetic gastroparesis significantly impacts quality of life due to upper gastrointestinal symptoms and poor glycemic control. New diagnostic tools and therapies are emerging to better manage this complex condition.
Area of Science:
- Gastroenterology
- Endocrinology
- Metabolic Diseases
Background:
- Diabetic gastroparesis is a serious complication of diabetes, affecting quality of life through gastrointestinal issues and impaired glycemic control.
- Current treatments, including optimized blood glucose, diet, and prokinetic/antiemetic drugs, have limitations.
- Gastric emptying (GE) rate is recognized as crucial for meal glycemic response.
Purpose of the Study:
- To review recent advancements in understanding diabetic gastroparesis.
- To emphasize current therapies affecting GE and the relationship between glycemic control and GE.
- To address uncertainties regarding hyperglycemia's impact on GE.
Main Methods:
- Literature review of recent advances in diabetic gastroparesis.
- Focus on therapies influencing gastric emptying.
- Analysis of the bidirectional relationship between glycemic control and GE.
Main Results:
- New diagnostic techniques are available to characterize gastroparesis mechanisms for personalized therapy.
- Existing management strategies for diabetic gastroparesis are complex and suboptimal.
- Understanding the interplay between hyperglycemia, gastric emptying, and glycemic control is evolving.
Conclusions:
- Diabetic gastroparesis management requires novel approaches.
- Personalized therapy based on individual gastroparesis mechanisms is a promising direction.
- Further research is needed to clarify the impact of longstanding hyperglycemia on GE.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:15Hypoglycemia and Glucagon
748
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
748
01:15Diabetes: Management and Pharmacotherapy
809
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
809
01:15Diabetes: Symptoms, Diagnosis, and Complications
1.9K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.9K
01:23Dipeptidyl Peptidase 4 Inhibitors
521
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
521
01:16Insulin: Dosing Regimen and Adverse Effects
615
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
615